Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

AACR 2018 /
First-in-human trial results of RET targeted BLU-667

14th - 18th Apr 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 25.04.18
Views: 4187

Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA

Dr Subbiah speaks with ecancer at AACR 2018 about results from a first-in-human clinical trial of RET targeted therapy.

RET alterations occur in tumours of many origins, and is currently treated with non-selective multi kinase inhibitors.

Among 43 patients with advanced solid tumours, BLU-667 elicited response rates of between 30-45%, depending on disease type.

The results are published in Cancer Discovery, and you can watch Dr Subbiah present the results in a press session here.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation